"There has been a great deal of debate about the effectiveness of bevacizumab in treating patients with glioblastoma," says Derek Johnson, M.D., a neuro-oncologist at Mayo Clinic Cancer Center and lead author of a new population-based study. "Our study found that, at the population level, treatment strategies involving bevacizumab prolonged survival in patients with progressive glioblastoma." Read more here.
Study mentioned: Johnson DR, et al. Glioblastoma survival in the United States improved after Food and Drug Administration approval of bevacizumab: A population-based analysis. Cancer. 2013 Jul 18. [Epub ahead of print] PMID: 23868553
No comments:
Post a Comment